Related references
Note: Only part of the references are listed.
Article
Oncology
Vicky Makker et al.
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In this study, researchers reported the long-term follow-up efficacy and safety data of lenvatinib plus pembrolizumab in previously treated advanced endometrial carcinoma patients, which showed extended efficacy and tolerability.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
H. K. van Halteren et al.
Summary: During the ESMO Congress 2022, outcome data of numerous clinical trials were presented. It is crucial for attending medical oncologists to organize these data in a way that helps find a balance between treatment burden and benefit.
Review
Oncology
Sushmita Gordhandas et al.
Summary: Endometrial cancer is the most common gynecologic malignancy worldwide, and its incidence and mortality are increasing. Systemic treatment options for advanced or recurrent EC have historically been limited, but with the identification of distinct EC subgroups and molecular drivers, precision oncology approaches and treatment advancements have emerged. This review provides an overview of current therapeutic options for advanced and recurrent EC and references the NCCN Guidelines for Uterine Neoplasms for diagnostic and management recommendations.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2023)
Article
Medicine, General & Internal
Ramez N. Eskander et al.
Summary: This study collected data from 816 patients with endometrial cancer and found that adding pembrolizumab to standard chemotherapy significantly prolonged progression-free survival in advanced or recurrent endometrial cancer patients compared to chemotherapy alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
M. R. Mirza et al.
Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Rebecca L. Siegel et al.
Summary: The American Cancer Society predicts that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. While incidence trends for most cancers are favorable, prostate cancer saw a significant increase of 3% annually from 2014 to 2019. However, the overall cancer death rate continues to decline due to advances in treatment, with a 33% reduction since 1991.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Medicine, General & Internal
V Makker et al.
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Junhwan Kim et al.
Summary: This study investigated the effectiveness and safety of pembrolizumab and lenvatinib for recurrent endometrial cancer in a real-world setting. The results showed lower treatment response rate and similar treatment discontinuation rate compared to clinical trials.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Medicine, General & Internal
Emma J. Crosbie et al.
Summary: Endometrial cancer is the most common gynaecological cancer in high income countries, with a global rise in incidence. Obesity is the major underlying cause, posing challenges for diagnosis and treatment. Early presentation with postmenopausal bleeding ensures cure, but advanced cases have poor prognosis. Minimally invasive surgical staging and targeted chemotherapeutic strategies are important advances.
Article
Oncology
Baoxia Gu et al.
Summary: The incidence of endometrial cancer (EC) has increased globally, while the mortality has decreased worldwide. There are significant differences between countries, and more efforts are needed to alleviate the disease burden of EC.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Medicine, General & Internal
Angela K. Green et al.
Summary: This study compared the differences in survival, duration of therapy, and treatment patterns between clinical trial patients and older adults with Medicare receiving cancer drugs for metastatic solid cancers in usual practice. The results showed that Medicare patients did not live as long as treated clinical trial participants and commonly received treatment modifications, indicating a lack of generalizability of cancer clinical data to Medicare beneficiaries with cancer.
Article
Oncology
Jeffrey A. How et al.
Summary: In recurrent endometrial cancer patients, pembrolizumab/lenvatinib combination therapy with a lower starting dose of lenvatinib (14 mg daily) was found to be safe and effective. There were no significant differences in response rates, survival outcomes, and toxicity between the recommended dose group and reduced dose group. However, the recommended dose group required more lenvatinib dose reductions and experienced quicker onset of treatment toxicity.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Chung-Han Lee et al.
Summary: Combination therapy of lenvatinib plus pembrolizumab showed promising antitumor activity and manageable safety profile in patients with metastatic RCC, providing a potential option for post-ICI treatment.
Article
Oncology
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Multidisciplinary Sciences
Tomoko Ozeki et al.
SCIENTIFIC REPORTS
(2019)
Review
Gastroenterology & Hepatology
Elena De Mattia et al.
WORLD JOURNAL OF GASTROENTEROLOGY
(2019)
Article
Oncology
J. Clarey et al.
ANNALS OF ONCOLOGY
(2012)
Article
Oncology
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER
(2009)
